SLCTR/2014/037已完成3 期
A Phase III Multicenter, Double-Blind, Randomized, Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects aged 10-17 years with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Merck Sharp and Dohme Corp0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects between the age of 10 to 17 years on day of signing informed consent with randomization to occur prior to 18th birthday.
- •2. Diagnosed Type 2 Diabetes Mellitus (T2DM)
- •3. Subject has not received treatment with insulin for at least 12 weeks prior to the screening visit
- •4. Hb A1C ?6.5% and ?10.0% on a stable dose of metformin immediate release or extended release (?1500 mg/day, for ?12 weeks)
- •5. Participant has a family member or adult closely involved in the daily activities and will participate in the subject's treatment and study protocol (i.e., available for telephone calls, study visits and administration of study medication as needed).
- •6. Informed consent from parent or guardian
排除标准
- •1. Known type 1 diabetes mellitus or documented evidence of positive diabetes auto-antibodies (if performed when patient was diagnosed with diabetes).
- •2. Known monogenic diabetes, secondary diabetes, or a genetic syndrome or disorder known to affect glucose tolerance other than diabetes.
- •3. Symptomatic hyperglycemia and/or moderate to large ketonuria requiring immediate initiation of another antihyperglycemic agent.
- •4.Subject has previously taken a DPP-4 inhibitor or GLP-1 receptor agonist
- •5. Initiation of chronic treatment with a medication known to cause weight gain OR weight loss
- •6. Current participation, or has participated within the prior 12 weeks, in a study in which the subject received an investigational compound or used an investigational device or is not willing to refrain from participating in another interventional study.
- •7. Currently on or likely to require treatment with >14 consecutive days or repeated courses of pharmacologic doses of corticosteroids
- •8. Undergone a surgical procedure within 4 weeks prior to signing informed consent or has major surgery planned during the study.
- •9. History of congenital heart disease or cardiovascular disease other than hypertension.
- •10. Visit 1 systolic or diastolic blood pressure of >95th percentile for age, height percentile and gender and is not considered likely to have values <95th percentile for age, height percentile and gender by Visit 3 with appropriate antihypertensive therapy.
- •11. History of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C (assessed by medical history), primary biliary cirrhosis, or symptomatic gallbladder disease.
- •12. Active nephropathy (i.e., nephrotic syndrome or glomerulonephritis). Note: Subjects with diabetic nephropathy will be eligible if they meet all other eligibility criteria.
- •13. Chronic myopathy, mitochondrial disorder or a progressive neurological or neuromuscular disorder
- •14. Human immunodeficiency virus (HIV) as assessed by medical history.
- •15. Clinically important hematological disorder (e.g. aplastic anemia, thrombocytopenia, myeloproliferative or myelodysplastic syndrome).
- •16. Current treatment for hyperthyroidism or on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks. Note: Subjects under treatment for hypothyroidism with a normal TSH value may participate.
- •17. Abnormal growth patterns or is being treated with growth hormone.
- •18. History of malignancy <5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
- •19. History of idiopathic acute pancreatitis or chronic pancreatitis.
- •20. Known history of recreational or illicit drug use, or of alcohol abuse or dependence (within the past year).
- •21. Has donated blood products or has had phlebotomy of >10% of estimated total blood volume within 8 weeks of signing informed consent, or intends to donate blood products or receive blood products within the projected duration of the study.
- •22. Known pregnancy, positive urine pregnancy test or breast-feeding, or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug.
- •23. Subject is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
- •24. History or current evidence of any condition, therapy, laboratory abnormality or other circumstanc
研究者
相似试验
进行中（未招募）
1 期
MK-0431A XR in Pediatric Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformain (Alone or in Combination with Insulin)Type 2 Diabetes MellitusEUCTR2012-004035-23-BGMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as223
进行中（未招募）
1 期
MK-0431A XR in Pediatric Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on MetformiType 2 Diabetes MellitusEUCTR2012-004035-23-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as240
进行中（未招募）
1 期
MK-1439A once a day versus ATRIPLA once a day in treatment-naïve HIV-1 infected subjectsHuman Immunodeficiency Virus-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2014-003382-17-PTMerck Sharp & Dohme LLC680
已完成
不适用
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects-B20 Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesHuman immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesB20PER-031-14MERCK SHARP & DOHME PERU S.R.L.,8
进行中（未招募）
不适用
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients - Safety and efficacy of once daily raltegravir compared to twice daily raltegravirHIV infectionMedDRA version: 11Level: PTClassification code 10020161Term: <Manually entered code. Term in E.1.1>EUCTR2008-002733-70-NLMSD BV750